Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Novavax Inc — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.89, while Novavax Inc trades at $7.98 (market cap $1.30B). The key difference: Novavax Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| LQD | NVAX | |
|---|---|---|
52-Week High | $112.91 | $11.19 |
52-Week Low | $106.96 | $6.22 |
Market Cap | — | $1.30B |
Sector | — | Health |
Enterprise Value | — | $800.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $107.15, down 0.38% with a bearish technical signal from moving averages. Recent dividend payments include $0.42 in May 2026 and $0.41 in June 2026, reflecting steady income distribution. The fixed income ETF sector shows renewed investor interest amid economic resilience and rate uncertainty, as noted by ETF Trends on July 14, 2026.
Outlook remains cautious due to technical weakness and Federal Reserve policy risks. Opportunities exist for income-focused investors seeking corporate bond exposure, but rising rate expectations pose headwinds. Key risks include inflation persistence and narrowing market breadth impacting bond valuations.
Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.
The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
